11 results about "GTPase" patented technology

Described herein, inter alia, are GTPase inhibitors and uses thereof.

Described herein, inter alia, are GTPase inhibitors and uses thereof.

Pharmaceutical compositions and therapeutic methods are provided comprising a single-domain antibody consisting of SEQ ID NO:1 and a pharmaceutically acceptable carrier. The antibody inhibits KRAS GTPase activity and inhibits phosphorylation of STAT3. In certain embodiments, inhibition of KRAS results in decreased phosphorylation of ERK1 / 2. The antibody reduces tumor cell surface PD-L1 expression and reduces VEGF production. The antibody crosses the blood-brain barrier following systemic administration and may exhibit sustained biological activity in vivo. Methods are provided for treating KRAS-mutant cancers, including pancreatic cancer and triple negative breast cancer, and for enhancing anti-tumor immunity through reduction of PD-L1 expression.

The invention belongs to the technical field of medical biology, and particularly relates to application of a detection reagent in a vascular targeted drug screening kit and a screening method. The detection reagent comprises a first detection reagent for detecting Rho GTP enzyme in experimental samples and a second detection reagent for detecting Rho kinase 2 in the experimental samples, the experimental samples comprise a first experimental sample and a second experimental sample, the first experimental sample comprises vascular endothelial cells highly expressed by Rho kinase 2, and the second experimental sample comprises vascular endothelial cells highly expressed by Rho kinase 2. The second experimental sample comprises hepatic stellate cells with high expression of Rho kinase 2; the blood vessel targeting drug is an anti-hepatic fibrosis drug taking a blood vessel as a target spot. The ROCK2 capable of targeting vascular endothelial cells and hepatic stellate cells at the same time can be effectively screened out, the anti-hepatic fibrosis medicine with the blood vessel as the target spot is further screened out, and a new thought is provided for screening of the anti-hepatic fibrosis medicine.

In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and / or GTPase IMAP Family Member 6 (Gimap6) in the HE and / or endothelial cells under conditions sufficient for stimulating formation of HSCs.

The present disclosure relates, in part, to a composition comprising a nucleic acid, wherein the nucleic acid encodes a protein which has a reduced abundance in a GTPase IMAP family 5 (GIMAP5) deficient subject or at least partially inhibits expression of a protein which has an increased abundance in a GIMAP5 deficient subject, as compared to a healthy subject. In certain embodiments, the composition is a nucleic acid-lipid particle. In certain embodiments, the composition is a polymer-based vehicle. In another aspect, the present disclosure relates to a recombinant viral vector comprising a nucleic acid encoding a protein which has a reduced abundance in a GIMAP5 deficient subject as compared to a healthy subject. In yet another aspect, the present disclosure provides a method of treating, ameliorating, and / or preventing liver disease and / or portal hypertension in a subject with administration of one or more compositions and / or vectors of the present disclosure.

It is an object of the present invention to provide a method for efficiently producing extracellular vesicles containing biologically active materials such as sonic hedgehog (Shh). The present invention provides, as a solution, a method for producing extracellular vesicles, comprising obtaining extracellular vesicles secreted from cells subjected to a treatment of inactivating Rab GTPase such as Rab18, wherein the cells are preferably cells expressing Shh. In addition, the present invention provides, as a solution, an extracellular vesicle containing Shh and having a particle diameter of 800 nm or more and / or a volume of 109 nm3 or more.

The invention provides application of Obg detection in liver cancer tissue in liver cancer treatment. The invention finds that EF-EVs derived from enterococcus faecalis deliver EF-Obg GTPase to activate a host mTOR pathway, thereby promoting liver cancer progression. The enterococcus faecalis Obg gene is very important for the enterococcus faecalis to activate mTOR so as to promote the occurrence of liver cancer, and the engineering Obg knocks down the enterococcus faecalis strain based on a CRISPRi (Clustered Regularly Interspaced Short Palindromic Repeats i) experiment. Clinically, abundant EF-Obg protein expression is related to activation enhancement of mTOR, so that the total lifetime of HCC patients is relatively poor. In addition, the treatment of the mTOR inhibitor everolimus is effective in an enterococcus faecalis colonized liver cancer in-situ model, which indicates that the treatment of everolimus is effective for liver cancer patients rich in enterococcus faecalis.

This invention relates to the field of electrochemical sensor sensing materials technology, and discloses a cardiovascular disease risk biomarker sensing material, its preparation method, and its application. The method includes the following steps: preparing a multi-dimensional carbon aerogel with a hierarchical porous structure; combining gold-loaded MXene with the multi-dimensional carbon aerogel to obtain a composite carbon aerogel; preparing a macromolecular electropolymerization solution containing o-phenylenediamine, labeled cMyBP-C, Rho GTPase, and calcium hydroxide; preparing a small molecule electropolymerization solution containing o-phenylenediamine, 3-NT, MDA, and Hcy; and electropolymerizing the small and macromolecular biomarkers separately using a two-step method, followed by cleaning to obtain the sensing material. This application utilizes the synergistic enhancement effect between carbon aerogel, MXene, and multi-template molecularly imprinted materials to achieve a unified high conductivity, high specific surface area, and high specificity recognition capability, enabling simultaneous, highly sensitive, and highly selective electrochemical detection of a cardiovascular disease risk biomarker spectrum composed of cMyBP-C, Rho GTPase, 3-NT, MDA, and Hcy.

The invention relates generally to the field of oncology. Provided herein is a method for predicting the likelihood of recurrence or prognosis of a cancer in a subject, comprising comparing the level of expression of one or more biomarkers selected from the group consisting of Fibroblast Growth Factor 2 (FGF2), Complement Component 3 (C3), and GTPase, IMAP Family Member 7 (GIMAP7) in a sample obtained from the subject to a reference. In particular, the cancer is nasopharyngeal cancer. Also provided is a composition or solid support comprising a plurality of DNA / RNA complexes, wherein each DNA / mRNA complex in the plurality comprises a biomarker and a first and second DNA probe hybridized to the biomarker, wherein the plurality of DNA / mRNA complexes comprise one or more biomarkers selected from the group consisting of FGF2, C3, and GIMAP7.

The present disclosure describes recombinant adeno-associated virus (rAAV) vectors which comprise a payload sequence encoding a synaptic GTPase-activating protein (SynGAP). The present disclosure also describes methods of treating SynGAP-related diseases, including neurodevelopmental disorders (NDDs) such as epileptic encephalopathies (DEEs).